Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

9.365 -0.085 (-0.90%)
Streaming Delayed Price Updated: 1:46 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LENZ Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
From Lenz Therapeutics, Inc.
Via GlobeNewswire
News headline image
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says ↗
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a... 
Via Benzinga
News headline image
Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study ↗
LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates significant improvement in Presbyopia, achieving primary and key secondary... 
Via Benzinga
News headline image
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
From LENZ Therapeutics, Inc.
Via Business Wire
News headline image
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
From LENZ Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.